Pharmacy Times spoke with Dr. Mark Pollack, MD, about Mental Health Awareness Month and the latest information on depression/medication adherence.
Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about how hospitals are tailoring their approaches to vaccine hesitancy to address social...
The investigational therapy RBX2660 has demonstrated positive trends in efficacy and safety for reducing recurrent Clostridioides difficile (C. difficile) infection over 6 months, in a recent study.
While the exact reason for the decreased immune response in middle-aged adults remains unclear, these findings suggest that this patient population may be continuously susceptible to the 3c2A H3N2 infection, even with immunization.
Lynlee Burton, head of the Center for Vaccines and Emerging Infectious Diseases at PRA Health Sciences, discusses the how the pandemic has impacted the way the United States views the pharmacist within the immunization space.